Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Benzinga Newsdesk www.benzinga.com Negative 54.3%

Neg 54.3% Neu 0% Pos 0%

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses of $(0.46) per share from the same period last year.